2017 Performance Improvement Report

STRATEGIC PRIORITY

1. Develop world-leading healthcare and research

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name** | | | |
| Improve compliance on use of primary prophylactic Granulocyte Colony Stimulating Factor (GCSF) | | | |
| **Site** | | **Department** | |
| Jeddah | | Oncology Department /Adult Medical Oncology Section | |
|  | | | |
| **Project Status** | **Project Start Date** | | **Project End Date** |
| Completed | 04-01-2017 | | 10-22-2017 |

|  |  |
| --- | --- |
| **Problem:** Why the project was needed?   1. As per National Comprehensive Cancer Network (NCCN) guidelines and American Society of Clinical Oncology (ASCO) guidelines, patients receiving chemotherapy with high risk for febrile neutropenia should receive primary prophylactic GCSF. 2. Docetaxel-based chemotherapy is considered treatment with high risk for FN (Febrile Neutropenia) 3. First phase of the audit (QI project) was conducted to determine the frequency of prescribing primary G-CSF prophylaxis to patients receiving docetaxel based chemotherapy between January 2015 and December 2015 (inclusive). | **Aims:** What will the project achieve?  Improve compliance on use of primary prophylactic Granulocyte Colony Stimulating Factor (GCSF) |
| **Benefits/Impact:** What is the improvement outcome?  *(check all that apply)*  Contained or reduced costs  Improved productivity  Improved work process  Improved cycle time  Increased customer satisfaction  Other (please explain)  Compliance with standard guidelines | **Quality Domain:** Which of the domains of healthcare quality does this project support?  *(Select only one)*  **Efficient** |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| |  |  | | --- | --- | | **Measures:** Performance metrics to be evaluated | **Targets:** Expected outcomes | | Compliance on use of primary prophylactic Granulocyte Colony Stimulating Factor (GCSF) | Improve compliance on use of primary prophylactic Granulocyte Colony Stimulating Factor (GCSF) from 58% to 70% in patients who receive docetaxel based chemotherapy. | |
| **Interventions:** Overview of key steps/work completed   * GCSF medication orders (filgrastim or pegfilgrastim) were embedded in the electronic Docetaxel-based chemotherapy protocols. |
| **Results:** Insert relevant graphs and charts to illustrate improvement pre and post project  *(insert relevant graphs, data, charts, etc.)*   1. Re-auditing was conducted after implementation of the corrective intervention to determine the frequency of prescribing primary G-CSF prophylaxis to patients receiving docetaxel based chemotherapy between April 1, 2017 and September 30, 2017 (inclusive). 2. The results showed that the use of prophylactic GCSF had improved from 58% (67/115) to 87% (46/53) in these cases. 3. Compliance rate improved by 29%. |

|  |  |
| --- | --- |
| **Project Lead** | **Team Members** |
| **Name**  *(person accountable for project)* | **Names**  *(persons involved in project)* |
| Zekri Jamal | Azhar Nawaz  Hossam Abdel Rahman  Imran Ahmad  Haleem Rasool  Ahmad Allithy  Reyad Dada  Ehab Abdelghany  Hind Mustafa  Kamel Farag  Saba Imtiaz  Sarbonza Meera |